GGrantIndex
← Leaderboards

Giuseppina Nucifora

Loyola University Chicago

Google Scholar ↗PubMed ↗ORCID ↗
$10,000,747
Attributed
$10,000,747
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.4M · FY2005–09
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$10,000,747 · 7

By mechanism

R01$9,689,007 · 6
R21$311,740 · 1

Top collaborators

No co-investigators on record.

Most similar at Loyola University Chicago

Same institution · by research overlap

Others in their field

Top investigators on “Neoplasm /Cancer Genetics”

Research focus

Neoplasm /Cancer GeneticsChronic Myelogenous LeukemiaTranscription FactorOncogenesGene Deletion MutationChimeric ProteinsLaboratory MouseCell DifferentiationCell CyclePathway InteractionsFusion GeneDoctor Of PhilosophyHuman SubjectProgramsClinical ResearchHematopoiesisBaseCellsAnimal ModelReporter GenesResearch PersonnelEvi1 GeneCell LineGenetic Transcription

Grant awards (32)

A Mouse Model of Myelodysplastic Syndrome Progression$367,420
R01 · FY2009 · HL · contact PI
Role of EVI1 Modifications in Cell Transformation$281,077
R01 · FY2009 · CA · contact PI
Inactivating EVI1 for the Treatment of Myelodysplastic *$367,420
R01 · FY2008 · HL · contact PI
A Mouse Model of Myelodysplastic Syndrome Progression$367,420
R01 · FY2008 · HL · contact PI
Role of EVI1 Modifications in Cell Transformation$281,077
R01 · FY2008 · CA · contact PI
A Mouse Model of Myelodysplastic Syndrome Progression$367,420
R01 · FY2007 · HL · contact PI
Inactivating EVI1 for the Treatment of Myelodysplastic *$367,420
R01 · FY2007 · HL · contact PI
Role of EVI1 Modifications in Cell Transformation$281,077
R01 · FY2007 · CA · contact PI
A Mouse Model of Myelodysplastic Syndrome Progression$378,394
R01 · FY2006 · HL · contact PI
Inactivating EVI1 for the Treatment of Myelodysplastic *$378,394
R01 · FY2006 · HL · contact PI
TEL, AML1, and TEL/AML1 in Hematopoiesis$342,467
R01 · FY2006 · HL · contact PI
Role of EVI1 Modifications in Cell Transformation$289,472
R01 · FY2006 · CA · contact PI
A Mouse Model of Myelodysplastic Syndrome Progression$387,500
R01 · FY2005 · HL
Inactivating EVI1 for the Treatment of Myelodysplastic *$387,500
R01 · FY2005 · HL
TEL, AML1, and TEL/AML1 in Hematopoiesis$350,708
R01 · FY2005 · HL
Role of EVI1 Modifications in Cell Transformation$296,438
R01 · FY2005 · CA
ANALYSIS OF MULTIPLE CHIMERIC TRANSCRIPTS IN THE T(3;21)$417,082
R01 · FY2004 · CA
TEL, AML1, and TEL/AML1 in Hematopoiesis$350,708
R01 · FY2004 · HL
INTERFERON ALPHA-INDUCED BIOLOGICAL RESPONSES IN CML$280,566
R01 · FY2004 · CA
EVI1 Expression is a Prognostic Marker of CML$155,870
R21 · FY2004 · CA
ANALYSIS OF MULTIPLE CHIMERIC TRANSCRIPTS IN THE T(3;21)$404,933
R01 · FY2003 · CA
TEL, AML1, and TEL/AML1 in Hematopoiesis$350,708
R01 · FY2003 · HL
INTERFERON ALPHA-INDUCED BIOLOGICAL RESPONSES IN CML$280,566
R01 · FY2003 · CA
EVI1 Expression is a Prognostic Marker of CML$155,870
R21 · FY2003 · CA
ANALYSIS OF MULTIPLE CHIMERIC TRANSCRIPTS IN THE T(3;21)$380,290
R01 · FY2002 · CA
INTERFERON ALPHA-INDUCED BIOLOGICAL RESPONSES IN CML$280,566
R01 · FY2002 · CA
ANALYSIS OF MULTIPLE CHIMERIC TRANSCRIPTS IN THE T(3;21)$344,261
R01 · FY2001 · CA
INTERFERON ALPHA INDUCED BIOLOGICAL RESPONSES IN CML$280,566
R01 · FY2001 · CA
MOLECULAR ANALYSIS OF TEL AND TEL/AML1 IN PREB LEUKEMIA$251,922
R01 · FY2001 · CA
ANALYSIS OF MULTIPLE CHIMERIC TRANSCRIPTS IN THE T(3;21)$256,235
R01 · FY2000 · CA
MOLECULAR ANALYSIS OF TEL AND TEL/AML1 IN PREB LEUKEMIA$243,400
R01 · FY2000 · CA
ANALYSIS OF MULTIPLE CHIMERIC TRANSCRIPTS IN THE T(3;21)$76,000
R01 · FY2000 · CA